Literature DB >> 3715810

Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro.

J Westwick, M F Scully, C Poll, V V Kakkar.   

Abstract

An unfractionated heparin (UFH) and a depolymerised derivative of low molecular weight heparin (LMWH) have been compared for their ability to activate platelets suspended in citrated plasma (PRP) or after washing and suspension in hepes buffered tyrode containing fibrinogen. Neither heparin alone induced aggregation of washed platelets, but UFH and to a much lesser extent LMWH, induced aggregation of platelets in PRP. Both heparins caused significant enhancement of a low concentration of ADP-induced activation of PRP and, again, the effect of LMWH was somewhat less than that of UFH. UFH produced a marked potentiation of ADP-induced activation of washed platelets and LMWH was about a third as potent. In addition, UFH induced a potentiation of PAF-induced aggregation and dense-granule release in PRP, a property not shared by LMWH. In PRP, UFH was three times more potent at inhibiting thrombin-induced aggregation and dense-granule release, as might be expected from their specific activities in the KCCT and thrombin time assay. However, with washed platelets, both heparins were equivalent at inhibiting thrombin-induced aggregation, dense-granule release and elevation of cytosolic free calcium ([Ca++]i) as monitored by quin 2 fluorescence. UFH and LMWH alone did not induce a change in [Ca++]i, nor had they any effect on ADP- or PAF-induced elevation of [Ca++]i.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3715810     DOI: 10.1016/0049-3848(86)90207-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

Review 1.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

2.  Heparin modulates the conformation and signaling of platelet integrin αIIbβ3.

Authors:  Mayumi Yagi; Jacqueline Murray; Kurt Strand; Scott Blystone; Gianluca Interlandi; Yasuo Suda; Michael Sobel
Journal:  Thromb Res       Date:  2011-12-23       Impact factor: 3.944

3.  Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.

Authors:  U Klinkhardt; J Graff; D Westrup; C M Kirchmaier; H U Esslinger; H K Breddin; S Harder
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

4.  Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial.

Authors:  S K Das; A T Cohen; R A Edmondson; E Melissari; V V Kakkar
Journal:  World J Surg       Date:  1996-06       Impact factor: 3.352

5.  Clinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.

Authors:  Jung Sun Cho; Sung-Ho Her; Ju Yeal Baek; Mahn-Won Park; Hyoung Doo Kim; Myung Ho Jeong; Young keun Ahn; Shung Chull Chae; Seung Ho Hur; Taek Jong Hong; Young Jo Kim; In Whan Seong; Jei Keon Chae; Jay Young Rhew; In Ho Chae; Myeong Chan Cho; Jang Ho Bae; Seung Woon Rha; Chong Jim Kim; Donghoon Choi; Yang Soo Jang; Junghan Yoon; Wook Sung Chung; Jeong Gwan Cho; Ki Bae Seung; Seung Jung Park
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

6.  Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.

Authors:  Jochen Graff; Ute Klinkhardt; Dagmar Westrup; Carl M Kirchmaier; Hans Klaus Breddin; Sebastian Harder
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 7.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

8.  The P2X1 receptor and platelet function.

Authors:  Martyn P Mahaut-Smith; Sarah Jones; Richard J Evans
Journal:  Purinergic Signal       Date:  2011-03-22       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.